Successful Desensitization to Dacarbazine Using Pretreatment with Omalizumab

Nagore Arruti, Sara Martínez, Jose Antonio Navarro, Susana Lizarza, Eva Lasa, Alejandro Joral, Miren Josune García de Andoin Barandiaran and Izaskun Zeberio Etxetxipia
Additional contact information
Alejandro Joral: Servicio de Alergología, Hospital Universitario Donostia, Spain
Miren Josune García de Andoin Barandiaran: Servicio de Farmacia, Hospital Universitario Donostia, Spain
Izaskun Zeberio Etxetxipia: Servicio de Hematología, Hospital Universitario Donostia, Spain

Biomedical Journal of Scientific & Technical Research, 2022, vol. 42, issue 1, 33304-33308

Abstract: Dacarbazine DTIC is an antineoplastic drug that belongs to the group of the alkylating agents...

Keywords: Medical Microbiology; Medical Case reports; Medical Drug and Therapeutics; Medical Humanities; Behavioral Medicine Journals; Neurological Disorders; Journals on Psychology; Regenerative Medicine; Family Medicine; Nano Medicine (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://biomedres.us/pdfs/BJSTR.MS.ID.006699.pdf (application/pdf)
https://biomedres.us/fulltexts/BJSTR.MS.ID.006699.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:abf:journl:v:42:y:2022:i:1:p:33304-33308

DOI: 10.26717/BJSTR.2022.42.006699

Access Statistics for this article

Biomedical Journal of Scientific & Technical Research is currently edited by Robert Thomas

More articles in Biomedical Journal of Scientific & Technical Research from Biomedical Research Network+, LLC
Bibliographic data for series maintained by Angela Roy ().